ABCD2 Score ≥4 Requires DAPT
For patients with high-risk TIA (ABCD2 score ≥4) or minor ischemic stroke (NIHSS ≤5), dual antiplatelet therapy (DAPT) with aspirin plus clopidogrel should be initiated within 24 hours of symptom onset and continued for 21 days, followed by single antiplatelet therapy. 1
Risk Stratification Threshold
The ABCD2 score threshold is ≥4 points (on a 0-7 scale, where 7 indicates worst stroke risk) to define high-risk TIA requiring DAPT 1, 2. This scoring system incorporates:
- Age (≥60 years = 1 point)
- Blood pressure (≥140/90 = 1 point)
- Clinical features (unilateral weakness = 2 points; speech disturbance without weakness = 1 point)
- Duration of symptoms (≥60 minutes = 2 points; 10-59 minutes = 1 point)
- Diabetes (present = 1 point)
Treatment Algorithm
Timing is Critical
- Initiate DAPT within 24 hours of symptom onset for maximum benefit 1, 3
- The therapeutic window appears to close around 42 hours, with declining benefit between 24-72 hours and potential harm beyond 72 hours 3
- Early initiation (within 24 hours) reduces 90-day stroke risk from 7.8% to 5.2% (HR 0.66) 2
Duration of Therapy
- Continue DAPT for 21 days to 3 weeks (benefit may be maximized as early as 21 days) 1, 2
- Switch to single antiplatelet therapy after this period
- Beyond 90 days, DAPT increases bleeding risk without additional stroke reduction benefit 1
Important Exclusions
This recommendation does NOT apply to patients with:
- Cardioembolic stroke (particularly atrial fibrillation—these patients need anticoagulation)
- Severe symptomatic intracranial large vessel stenosis (≥70%)
- Patients who received acute thrombolysis
- Low-risk TIA (ABCD2 <4) 1
Common Pitfalls
Delayed initiation: The most critical error is waiting beyond 24 hours to start DAPT. The benefit diminishes rapidly, with no significant benefit between 24-72 hours and potential harm after 72 hours 3.
Prolonged DAPT duration: Continuing DAPT beyond 90 days increases bleeding risk without reducing stroke recurrence 1. Triple therapy (aspirin + clopidogrel + dipyridamole) is explicitly not recommended due to increased bleeding without benefit 1.
Active cancer patients: Those with active malignancy have substantially higher risks of both ischemic events (HR 2.75) and bleeding (HR 2.51) on DAPT, particularly with hematological malignancies 4. Consider this high-risk subgroup carefully.
Evidence Strength
The 2021 AHA/ASA guideline 1 provides the definitive framework, supported by multiple randomized trials showing DAPT reduces early recurrent stroke risk when initiated promptly in appropriately selected patients. The ABCD2 ≥4 threshold is consistently validated across both guideline recommendations and recent real-world studies 2, 5.